Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma.
- DOI
- 10.1007/s00277-010-0925-1
- Published
- 2010-03-16
- Container
- Ann Hematol
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s00277-010-0925-1,
title = {Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma.},
author = {Palumbo A and Davies F and Kropff M and Bladé J and Delforge M and Leal da Costa F and Garcia Sanz R and Schey S and Facon T and Morgan G and Moreau P.},
year = {2010},
journal = {Ann Hematol},
doi = {10.1007/s00277-010-0925-1},
url = {https://doi.org/10.1007/s00277-010-0925-1}
}RIS
TY - JOUR TI - Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. AU - Palumbo A AU - Davies F AU - Kropff M AU - Bladé J AU - Delforge M AU - Leal da Costa F AU - Garcia Sanz R AU - Schey S AU - Facon T AU - Morgan G AU - Moreau P. PY - 2010 JO - Ann Hematol DO - 10.1007/s00277-010-0925-1 UR - https://doi.org/10.1007/s00277-010-0925-1 ER -
APA
A, P., F, D., M, K., J, B., M, D., F, L. D. C., R, G. S., S, S., T, F., G, M., & P., M. (2010). Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma.. Ann Hematol. https://doi.org/10.1007/s00277-010-0925-1
Source records
- europe-pmc · retrieved 2026-09-26T22:08:36.167Z
- hal · retrieved 2026-09-26T22:08:36.299Z